ten23 health settles in Basel

Ten23 health has announced that it has commenced operations in Basel. Its company headquarters are located on the Rosental Mitte campus. A new working environment for 150 full-time positions is being offered over 4,000 square meters of laboratory and office space in the building that was formerly home to Elanco.

The company hopes to use its scientific competence and its “globally recognized” expertise in industry and regulations to support clients from the global biotech and pharmaceutical industries with the development, manufacture, and testing of injectable biopharmaceuticals. It is “solidly financed” through the commitment of the UK-based associated company 3i Group.

Ten23 health states that it is led by a world-class leadership team and is able to demonstrate “outstanding expertise” in the biopharmaceutical industry, pharmaceutical and analytical sciences, development, and regulatory requirements. The team headed up by CEO Prof. Dr. Hanns-Christian Mahler has “a proven track record in the field of pharmaceutical product design and development” as well as an “extensive global pharma network”.

The CEO adds: “Our comprehensive offering will allow our clients to focus on the medicine and the patient, whilst leveraging our pharmaceutical expertise and knowledge to plan and de-risk product development.” The aim is to enable rapid, high-quality, successful commercialization.

Richard Relyea, a Partner at 3i and a Member of the Board of Directors of ten23 health, emphasizes the holistic approach of ten23 health, saying: “We will deliver services in an engrained, fair and sustainable manner.” By investing in ten23 health, 3i intends to support “the establishment of a uniquely differentiated partner to leading global biotech and pharmaceutical customers”.